Search

Guy S Salvesen

from Encinitas, CA
Age ~69
Get Report
Also known as:
Guy A Salvesen
Phone and address:
1936 Circle Park Ln, Encinitas, CA 92024
(760) 634-5648
Related to:
Lirgo Van, 59Gabrielle V Lingen, 65Robert Bachman, 92Michael V Lingen, 60Michael Vanlingen, 29
Connected to:
Arne E Salvesen, 112Heather Salvesen, 40Jan A Salvesen, 88Karina M Salvesen, 49Kay Salvesen, 69Lauren K Salvesen, 34Magda A Salvesen, 80Orville K Salvesen, 43Savannah Salvesen, 36Andrew T Salveson, 54

Guy Salvesen Phones & Addresses

  • 1936 Circle Park Ln, Encinitas, CA 92024 (760) 634-5648
  • La Jolla, CA
  • Chapel Hill, NC
  • San Diego, CA
  • Durham, NC
  • 1936 Circle Park Ln, Encinitas, CA 92024

Work

Company: Sanford-burnham medical research institute 1996 Position: Professor

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Cambridge 1977 to 1981 Specialities: Biochemistry, Philosophy

Skills

Biochemistry • Molecular Biology • Cell Biology • Cell

Industries

Research

Resumes

Resumes

Guy Salvesen Photo 1

Professor

View page
Location:
1936 Circle Park Ln, Encinitas, CA 92024
Industry:
Research
Work:
Sanford-Burnham Medical Research Institute since 1996
Professor
Education:
University of Cambridge 1977 - 1981
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy
Skills:
Biochemistry
Molecular Biology
Cell Biology
Cell

Publications

Wikipedia References

Guy Salvesen Photo 2

Guy Salvesen

Work:
Company:

Duke University faculty

Education:
Specialty:

Biochemist • Director

Area of science:

Biochemistry

Academic degree:

PHD

Skills & Activities:

, Dummitt, B., Chang, Y. H., Mast, A. E., Eroshkin, A., Smith, J., Tao, W. A. and Salvesen, G....

Us Patents

Compositions And Methods For The Screening Pro-Apoptotic Compounds

View page
US Patent:
7067274, Jun 27, 2006
Filed:
Nov 8, 2004
Appl. No.:
10/983495
Inventors:
Wayne J. Fairbrother - Burlingame CA, US
Matthew C. Franklin - San Francisco CA, US
Heidi Jenii Ackerly Wallweber - La Honda CA, US
Linda Orren Elliott - Half Moon Bay CA, US
Saloumeh Kadkhodayan - Castro Valley CA, US
Domagoj Vucic - San Francisco CA, US
Guy Salvesen - Encinitas CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
The Burnham Institute - Encinitas CA
International Classification:
C12Q 1/00
C12Q 1/37
G01N 33/53
US Classification:
435 23, 435 71, 435 6
Abstract:
The present invention is directed to compositions of matter useful for the enhancement of apoptosis in mammals and to methods of using those compositions of matter for the same.

Screening Assays For Agents That Alter Inhibitor Of Apoptosis (Iap) Protein Regulation Of Caspase Activity

View page
US Patent:
7192728, Mar 20, 2007
Filed:
Mar 5, 2001
Appl. No.:
09/799994
Inventors:
John C Reed - Rancho Santa Fe CA, US
Quinn Deveraux - San Diego CA, US
Guy S Salvesen - Encinitas CA, US
Ryosuke Takahashi - San Diego CA, US
Natalie Roy - La Jolla CA, US
Assignee:
The Burnham Institute - La Jolla CA
International Classification:
C12Q 1/34
G01N 33/53
US Classification:
435 18
Abstract:
The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.

Screening Assays For Agents That Alter Inhibitor Of Apoptosis (Iap) Protein Regulation Of Caspase Activity

View page
US Patent:
7794961, Sep 14, 2010
Filed:
Jan 9, 2007
Appl. No.:
11/651651
Inventors:
John C. Reed - Rancho Santa Fe CA, US
Quinn Deveraux - San Diego CA, US
Guy S. Salvesen - Encinitas CA, US
Ryosuke Takahashi - Tokyo, JP
Natalie Roy - La Jolla CA, US
Assignee:
Sanford-Burnham Medical Research Institute - La Jolla CA
International Classification:
G01N 33/574
US Classification:
435 723, 435 721
Abstract:
The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.

Screening Assays For Agents That Alter Inhibitor Of Apoptosis (Iap) Protein Regulation Of Caspase Activity

View page
US Patent:
8071327, Dec 6, 2011
Filed:
Aug 2, 2010
Appl. No.:
12/848936
Inventors:
John C. Reed - Rancho Santa Fe CA, US
Quinn Deveraux - San Diego CA, US
Guy S. Salvesen - Encinitas CA, US
Ryosuke Takahashi - Kokubunji, JP
Natalie Roy - La Jolla CA, US
Assignee:
Sanford-Burnham Medical Research Institute - La Jolla CA
International Classification:
C12Q 1/34
US Classification:
435 18
Abstract:
The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.

Screening Assays For Agents That Alter Inhibitor Of Apoptosis (Iap) Protein Regulation Of Caspase Activity

View page
US Patent:
20010018195, Aug 30, 2001
Filed:
Mar 5, 2001
Appl. No.:
09/799463
Inventors:
John Reed - Rancho Santa Fe CA, US
Quinn Deveraux - San Diego CA, US
Guy Salvesen - Encinitas CA, US
Ryosuke Takahashi - San Diego CA, US
Natalie Roy - La Jolla CA, US
Assignee:
THE BURNHAM INSTITUTE
International Classification:
C12Q001/34
G01N033/53
US Classification:
435/018000, 435/007100
Abstract:
The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells.

Fusion Proteins And Methods Of Cleavage Of Such Proteins

View page
US Patent:
20070141662, Jun 21, 2007
Filed:
May 24, 2006
Appl. No.:
11/439896
Inventors:
Henning Stennicke - Kokkedal, DK
Lars Iversen - Holte, DK
Guy Salvesen - Encinitas CA, US
Assignee:
Novo Nordisk A/S - Bagsvaerd
The Burnham Institute - La Jolla CA
International Classification:
C12P 21/06
A61K 38/28
C07K 14/745
C07K 14/56
US Classification:
435068100, 530303000, 530351000, 530383000
Abstract:
The invention provides a method of processing recombinant proteins by using aspartate specific proteases.

Screening Assays For Agents That Alter Inhibitor Of Apoptosis (Iap) Protein Regulation Of Caspase Activity

View page
US Patent:
20120094922, Apr 19, 2012
Filed:
Nov 2, 2011
Appl. No.:
13/287979
Inventors:
John C. Reed - Rancho Santa Fe CA, US
Quinn Deveraux - San Diego CA, US
Guy S. Salvesen - Encinitas CA, US
Ryosuke Takahashi - Tokyo, JP
Natalie Roy - La Jolla CA, US
Assignee:
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 38/02
A61P 35/00
A61P 25/28
C12Q 1/37
G01N 33/573
US Classification:
514 189, 435 23, 435 71
Abstract:
The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP.

Intranasal Delivery Of Cell Permeant Therapeutics

View page
US Patent:
20140024597, Jan 23, 2014
Filed:
Feb 15, 2013
Appl. No.:
13/768687
Inventors:
The Trustees of Columbia University in the City of New York - , US
Nsikan Akpan - New York NY, US
Guy Salvesen - Encinitas CA, US
Scott Snipes - La Jolla CA, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 38/16
US Classification:
514 177
Abstract:
The present invention relates to compositions and methods for the inhibition of apoptosis associated with ischemic injury in the central nervous system. In addition, the present invention relates to compositions and methods useful for extending the therapeutic window associated with ischemic injury.
Control profile
Guy S Salvesen from Encinitas, CA, age ~69 Get Report